Navigation Links
Transcept Pharmaceuticals to Present at Rodman & Renshaw and Stifel Nicolaus Investor Conferences in September 2010
Date:9/7/2010

Transcept Pharmaceuticals to Present at Rodman & Renshaw and Stifel Nicolaus Investor... -- POINT RICHMOND, Calif., Sept. 7 /PRNewswire-FirstCall/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Banking & Financial Services, Health Care & Hospitals, Pharmaceuticals, Trade Show News Click to view news release full screen  

Transcept Pharmaceuticals to Present at Rodman & Renshaw and Stifel Nicolaus Investor Conferences in September 2010

 

POINT RICHMOND, Calif., Sept. 7 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc.  (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced that Transcept management is scheduled to participate in these upcoming investor conferences:Rodman and Renshaw Annual Global Investment ConferenceNew York, NYSeptember 14, 2010 at 5:20 p.m. EDTA live audio webcast and replay of this presentation may be accessed at http://www.wsw.com/webcast/rrshq18/tspt and on the Transcept Investor webpage at www.transcept.com.Stifel Nicolaus Healthcare ConferenceBoston, MASeptember 16, 2010 at 9:10 a.m. EDTA live audio webcast and replay of this presentation may be accessed at http://www.veracast.com/webcasts/stifel/healthcare2010/65203465.cfm and on the Transcept Investor webpage at www.transcept.com.About TransceptTranscept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. The most advanced Transcept product candidate is Intermezzo® (zolpidem tartrate sublingual tablet), for which a New Drug Application (NDA) was submitted to the U.S. Food and Drug Administration (FDA) in September 2008 seeking approval as a prescription sleep aid for use in the middle of the night at the time a patient awakens and has difficulty returning to sleep. In October 2009, Transcept received a Complete Response Letter from the FDA on the Intermezzo® NDA and is working to respond to issues raised in the letter. Transcept and Purdue Pharmaceutical Products L.P. have entered into a collaboration agreement for the development and commercialization of Intermezzo® in the United States.  Transcept is also developing TO-2061, an ultra low dose ondansetron augmentation therapy for patients with obsessive compulsive disorder (OCD) who have not adequately responded to treatment with SSRIs.  Transcept plans to begin a Phase 2 study of TO-2061 in 2011.  For further information, please visit the Transcept website at: www.transcept.com.

Contact:Transcept Pharmaceuticals, Inc.Greg MannDirector, Corporate Communications(510) 215-3567gmann@transcept.com
'/>"/>

SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Transcept Pharmaceuticals Receives Notice of Allowance for Second U.S. Patent Application Covering Intermezzo(R)
2. Transcept Pharmaceuticals Scheduled to Meet With FDA to Discuss Intermezzo(R) Complete Response Letter
3. Transcept Pharmaceuticals Reports Third Quarter 2009 Financial Results
4. Transcept Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference on November 17
5. Transcept Pharmaceuticals to Report Third Quarter 2009 Results and Host Conference Call on November 12
6. Transcept Pharmaceuticals Receives Complete Response Letter from FDA on Intermezzo(R) New Drug Application
7. Transcept Pharmaceuticals to Report First Quarter 2009 Results
8. Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings
9. Transcept Pharmaceuticals Announces Intent to Submit New Drug Application for Intermezzo(R) in Third Quarter 2008
10. Cadence Pharmaceuticals to Present at Four Investment Conferences During the Month of September 2010
11. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... , Dec. 2, 2016 The U.S. ... for Jardiance (empagliflozin) to reduce the risk of cardiovascular ... and cardiovascular disease. "Cardiovascular disease is ... 2 diabetes mellitus," said Jean-Marc Guettier , M.D., ... Products in FDA,s Center for Drug Evaluation and Research. ...
(Date:12/2/2016)... , December 2, 2016 bioLytical Laboratories, un líder ... Compañía, el INSTI HIV Self Test , a los miembros de la ... ... INSTI HIV Self Test! (PRNewsFoto/bioLytical Laboratories) ...      (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) bioLytical ...
(Date:12/2/2016)... the ECG Cables And ECG Leadwires Market owing to the ... On the other hand, the Asia-Pacific ... during the forecast period. The market players namely, ... ( Ireland ), Koninklijke Philips N.V. ( ... China ), held major share of the ECG ...
Breaking Medicine Technology:
(Date:12/5/2016)... ... December 05, 2016 , ... As renowned, board-certified dermatologists, ... dangers and downsides of patients who do not do their research and undergo cosmetic ... dermatology is in the midst of a renaissance and every other month a new ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... they have teamed up with The American College of Surgeons (ACS) to provide ... on Trauma, the “Bleeding Control Basic” course is a pilot program that fulfills ...
(Date:12/4/2016)... ... December 03, 2016 , ... The Lymphoma Research ... lymphoma research and serving the lymphoma community through a comprehensive series of education ... Tasting Event in New York City, with long-time partners The Paul Foundation, on ...
(Date:12/4/2016)... ... December 03, 2016 , ... ... Shaping" at the 2016 Anti-Aging & Beauty Awards at The Aesthetic ... Aesthetic & Anti-Aging Medicine European Congress (AMEC) brings together the industry’s leading ...
(Date:12/4/2016)... , ... December 04, 2016 , ... ... major cosmetic surgery can now take advantage of a cosmetic procedure known as ... rejuvenation treatment that reduces the appearance of age spots, fine lines, uneven ...
Breaking Medicine News(10 mins):